argenx (NASDAQ: ARGX) is one of 92 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare argenx to similar businesses based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, risk and institutional ownership.
This table compares argenx and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares argenx and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|argenx||$44.74 million||-$31.73 million||-69.11|
|argenx Competitors||$1.03 billion||$94.79 million||-1.72|
argenx’s peers have higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings for argenx and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
argenx presently has a consensus price target of $108.50, suggesting a potential upside of 12.14%. As a group, “Biological products, except diagnostic” companies have a potential upside of 16.02%. Given argenx’s peers higher possible upside, analysts clearly believe argenx has less favorable growth aspects than its peers.
Institutional & Insider Ownership
52.8% of argenx shares are held by institutional investors. Comparatively, 51.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 17.5% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.